Pro 2013-007 (Announcement of Jianfeng Group on Providing Counter-Guarantees to Corporate Bond Counter-Guarantors)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2013-007
浙江尖峰集团股份有限公司
关于向公司债券反担保人提供反担保的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l本次担保的被担保人(质押权人)名称:天津帝士力投资控股集团有限公司
l本次担保金额:公司拟发行的规模不超过6亿元公司债券的本金及利息
l本次担保是否有反担保:本次对外担保实质是为公司发行公司债进行反担保
l对外担保逾期的累计数量:无
一、担保情况概述
2013年1月22日,公司召开的2013年第一次临时股东大会已批准关于公司发行票面总额不超过6亿元、期限不超过7年的公司债的相关议案,并授权董事会根据市场情况确定本次公司债券是否采用担保及具体担保方式,授权董事会及其授权人士(董事长、董事会秘书)全权办理本次发行公司债券相关事项。详见本公司2013年1月5日披露的《第八届董事会第八次会议决议公告》、《关于发行公司债券方案的公告》和2013年1月23日披露的《2013年第一次临时股东大会决议公告》,上述公告分别披露在《上海证券报》、《中国证券报》和上海证券交易所网站(http://www.sse.com.cn)上。
2013年2月26日,浙江尖峰集团股份有限公司以通信方式召开了第八届第九次董事会,公司现有董事9名,全部出席了本次会议,关联董事蒋晓萌先生、杜自弘先生回避了部分议案的表决,符合《公司法》和《公司章程》的有关规定,所做决议合法有效。经审议与表决,董事会以7票同意、0票反对、0票弃权审议通过了《关于向公司债券反担保人提供反担保的议案》。
为增强本次公司债的偿债保障,降低发行利率,本公司确定由天津天士力集团有限公司(以下简称:天士力集团)为本次公司债提供全额无条件的不可撤销的连带责任保证担保;由天士力集团的大股东天津帝士力投资控股集团有限公司(以下简称:帝士力控股)为天士力集团在该担保责任范围内提供保证方式的反担保。
由本公司将所持有的天士力集团20.76%股权质押给本次公司债券反担保人帝士力控股,作为本公司向帝士力控股在其担保责任范围内提供的反担保。授权公司董事长签署与上述担保及反担保相关的所有法律文件。
本次股权质押的质权人帝士力控股与本公司不存在关联关系;因本公司董事蒋晓萌先生和杜自弘先生也同时担任天士力集团的董事,根据上海证券交易所《股票上市规则》的相关规定,天士力集团是本公司的关联方。
二、被担保人(质押权人)基本情况
1、被担保人(质押权人)名称:天津帝士力投资控股集团有限公司。
2、成立时间: 1998年11月12日。
3、住所:天津北辰科技园区。
4、法定代表人:闫希军。
5、注册资本:3500万元。
6、经营范围:技术开发、咨询、服务、转让生物技术及产品,以自有资金对保健食品、高科技行业进行投资。
7、与本公司关系:帝士力控股为本公司联营公司天士力集团的第一大股东,与本公司不存在关联关系。
8、财务情况:
按经审计的合并财务报表口径,截至2011年末,帝士力控股资产总额1,110,405.48万元,负债总额683,441.77万元,所有者权益合计(含少数股东权益)426,963.71万元。2011年度,实现营业收入978,075.32万元,净利润(含少数股东权益)31,842.31万元。
按未经审计的合并财务报表口径,截至2012年三季度末,帝士力控股资产总额1,135,037.33万元,负债总额663,027.71万元,所有者权益合计(含少数股东权益)472,009.62万元;2012年1-9月,实现营业收入730,728.46万元,净利润(含少数股东权益)56,912.14万元。
三、股权质押反担保的主要内容
(一)股权质押反担保内容
天士力集团为本公司拟发行的票面总额不超过6亿元、期限不超过7年的公司债提供全额无条件不可撤消的连带责任保证担保。由帝士力控股为天士力集团在该担保责任范围内提供保证方式的反担保。
本公司将所持有的天士力集团20.76%股权质押给帝士力控股,作为本公司向帝士力控股在其担保责任范围内提供的反担保。
(二)用于设定质押的反担保资产情况
公司本次用于反担保的质押资产是所持有的天士力集团20.76%股权,截止2011年末,该部分股权的投资成本为5,067.34万元。
1、天士力集团成立于2000年3月30日,注册地址:天津北辰科技园区,现有注册资本:23,784.38万元,其中:帝士力控股占61.68%、本公司占20.76%。经营范围:对外投资、控股;天然植物药种植及相关加工、分离;组织所属企业开展产品的生产、科研、销售、进出口经营业务;各类商品、物资的批发、零售;技术开发、咨询、服务、转让生物技术(不含药品生产与销售)及产品等。天士力集团是以大健康产业为主线,以制药业为中心,集生产、投资于一体的多元化集团企业。截止2012年9月末,天士力集团持有上市公司天士力制药集团股份有限公司47.27%的股权。
2、用于设定质押的反担保资产账面价值:截至2011年12月31日,反担保资产经审计的长期股权投资帐面价值35,239.73万元。截至2012年9月30日,反担保资产未经审计的长期股权投资帐面价值46,012.89万元。
3、用于设定质押的反担保资产在用于本次质押前不存在质押或者其他第三人权利、不涉及诉讼、仲裁事项,不存在查封、冻结等司法措施等情形以及妨碍权属转移的其他情况。
4、天士力集团2011年度财务报告经具从事证券、期货业务资格的天健会计师事务所(特殊普通合伙)审计,并出具标准无保留意见的审计报告。截至2011年12月31日,天士力集团经审计的合并口径资产总额1,041,815.88万元,负债总额634,383.72万元,归属于母公司所有者权益合计169,366.60万元。2011年度,实现主营业务收入927,977.29万元,利润总额86,209.96万元,归属于母公司所有者的净利润24,656.61万元。
截至2012年9月末,天士力集团未经审计的合并口径资产总额1,090,843.81万元,负债总额612,510.59万元,归属于母公司所有者权益合计221,974.93万元。2012年1-9月,实现主营业务收入694,726.89万元,利润总额104,716.12万元,归属于母公司所有者的净利润56,550.32万元。
四、董事会意见
1、股权质押反担保的必要性
由天士力集团为本次公司债券提供担保能切实增强公司债的偿债保障,有利于降低债券发行成本。帝士力控股向天士力集团提供保证方式的反担保,同时本公司对帝士力控股提供股权质押方式的反担保,是本次公司债券担保方案的组成部分,已经2013年第一次临时股东大会决议授权。上述反担保措施符合本公司及股东的整体利益。
2、股权质押反担保风险
由帝士力控股向天士力集团提供保证方式的反担保, 本公司向帝士力控股提供股权质押方式的反担保,实质是为本公司自身的融资进行担保。只要本公司能够按期偿还公司债券的本息,本次股权质押反担保的风险很小,不会影响公司经营。
五、累计对外担保数量及逾期担保的数量
截止本公告披露日,公司及其控股子公司已批准的对外担保总额为7,000.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的4.93%;公司对控股子公司已批准的担保总额为73,000.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的51.40%。
截止本公告披露日,公司及其控股子公司对外担保实际余额为7,000.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的4.93%;公司对控股子公司的担保实际余额为18,481.00万元,占公司2011年经审计的合并口径归属于母公司所有者权益合计的13.01%。
截止本公告披露日,本公司没有逾期担保。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一三年二月二十六日
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05